CD44 | CD44 molecule (Indian blood group) | Blood group antigen proteins Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CD52 | CD52 molecule | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
CD80 | CD80 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD86 | CD86 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
CES1 | Carboxylesterase 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
CFTR | Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CHD1 | Chromodomain helicase DNA binding protein 1 | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
CHRFAM7A | CHRNA7 (cholinergic receptor, nicotinic, alpha 7, exons 5-10) and FAM7A (family with sequence similarity 7A, exons A-E) fusion | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
CHRM1 | Cholinergic receptor, muscarinic 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CHRM2 | Cholinergic receptor, muscarinic 2 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CHRM3 | Cholinergic receptor, muscarinic 3 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
CHRM4 | Cholinergic receptor, muscarinic 4 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CHRM5 | Cholinergic receptor, muscarinic 5 | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
CHRNA10 | Cholinergic receptor, nicotinic, alpha 10 (neuronal) | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
CHRNA2 | Cholinergic receptor, nicotinic, alpha 2 (neuronal) | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
CHRNA3 | Cholinergic receptor, nicotinic, alpha 3 (neuronal) | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
CHRNA4 | Cholinergic receptor, nicotinic, alpha 4 (neuronal) | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CHRNA7 | Cholinergic receptor, nicotinic, alpha 7 (neuronal) | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
CHRNB2 | Cholinergic receptor, nicotinic, beta 2 (neuronal) | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
CHRNB4 | Cholinergic receptor, nicotinic, beta 4 (neuronal) | FDA approved drug targets Predicted membrane proteins
| | | | | Group enriched |
CKB | Creatine kinase, brain | Cancer-related genes Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CKM | Creatine kinase, muscle | Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
CKMT1A | Creatine kinase, mitochondrial 1A | Enzymes FDA approved drug targets Mitochondrial proteins Predicted secreted proteins
| | | | | Mixed |
CKMT1B | Creatine kinase, mitochondrial 1B | Enzymes FDA approved drug targets Mitochondrial proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CKMT2 | Creatine kinase, mitochondrial 2 (sarcomeric) | Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
CLCN2 | Chloride channel, voltage-sensitive 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
CNR1 | Cannabinoid receptor 1 (brain) | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CNR2 | Cannabinoid receptor 2 (macrophage) | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
COMT | Catechol-O-methyltransferase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CPS1 | Carbamoyl-phosphate synthase 1, mitochondrial | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CPT2 | Carnitine palmitoyltransferase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CRBN | Cereblon | Disease related genes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
CSF2RA | Colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CSF2RB | Colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CSF3R | Colony stimulating factor 3 receptor (granulocyte) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CTLA4 | Cytotoxic T-lymphocyte-associated protein 4 | CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CXCR4 | Chemokine (C-X-C motif) receptor 4 | Cancer-related genes CD markers Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Expressed in all |
CYP11B1 | Cytochrome P450, family 11, subfamily B, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins
| | | | | Tissue enriched |
CYP17A1 | Cytochrome P450, family 17, subfamily A, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
CYP19A1 | Cytochrome P450, family 19, subfamily A, polypeptide 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
CYP51A1 | Cytochrome P450, family 51, subfamily A, polypeptide 1 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CYSLTR1 | Cysteinyl leukotriene receptor 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Mixed |
CYSLTR2 | Cysteinyl leukotriene receptor 2 | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
DBH | Dopamine beta-hydroxylase (dopamine beta-monooxygenase) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
DCK | Deoxycytidine kinase | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
DDC | Dopa decarboxylase (aromatic L-amino acid decarboxylase) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
DDR2 | Discoidin domain receptor tyrosine kinase 2 | CD markers Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
DHFR | Dihydrofolate reductase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Mixed |
DHODH | Dihydroorotate dehydrogenase (quinone) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |